Brookstone Capital Management cut its stake in Novo Nordisk A/S (NYSE:NVO – Free Report) by 9.9% in the fourth quarter, ...

The head of Ozempic maker Novo Nordisk A/S is among business executives who are meeting the Danish prime minister to discuss ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Capital Investment Advisors LLC increased its stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 12.1% during ...

DKK 320 million has been awarded for the development of a new campus that will provide the setting for close collaboration ...

Europe’s aging population drives automation, with robots enhancing productivity, but high costs and challenges remain.

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

The liver cirrhosis treatment market is poised for significant growth, driven by the rising global prevalence of liver diseases, particularly NAFLD, fueled by lifestyle factors like obesity, alcohol ...